What is the prevalence of Atopic Dermatitis and Eczema?

Atopic dermatitis and eczema is a common, chronic inflammatory skin condition that affects an estimated 15% to 20% of children and 1% to 3% of adults globally, though prevalence rates vary significantly by region and diagnostic criteria.

Prevalence and Classification

Unlike many conditions mapped on our platform, atopic dermatitis and eczema is considered a common, non-rare disease in most industrialized nations. Because it is highly prevalent, incidence rates are difficult to track with precision, though it remains the most common chronic skin disorder in pediatric populations. While the majority of cases emerge in infancy, atopic dermatitis and eczema can persist into or first manifest during adulthood.

Demographic and Geographic Variations

Epidemiological data suggests that atopic dermatitis and eczema affects males and females nearly equally, though some studies indicate a slight female predominance in adulthood. Prevalence is notably higher in urbanized, high-income countries compared to rural or developing regions, a phenomenon often attributed to the "hygiene hypothesis." Ethnic variations also exist, with higher reported rates and often more severe clinical presentations observed in Black and Asian populations compared to White populations.

Challenges in Data Collection

Accurate prevalence data for atopic dermatitis and eczema is frequently hindered by the lack of a single, universal diagnostic test. Many cases go underreported or are misdiagnosed as other forms of contact or irritant dermatitis. Furthermore, the intermittent nature of flares means that many individuals may not seek medical attention during periods of remission, leading to an underestimation of the true burden of disease. Our community at DiseaseMaps.org provides a vital, complementary perspective; by gathering real-world experiences from 643 members, we can better understand the day-to-day impact that clinical statistics often overlook, such as sleep disruption and psychological burden.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)


• Orphanet: Portal for rare diseases and orphan drugs


• NIH Genetic and Rare Diseases Information Center (GARD)